Current management of glaucoma

Current Opinion in Ophthalmology

Volumn 15, Issue 2, 2004, Pages 119-126

  Schwartz, Kenneth ^a   Budenz, Donald ^b,c  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Filtering surgery; Glaucoma; Prostaglandin; SLT

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIFIBROTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BIMATOPROST; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; DORZOLAMIDE; FLUOROURACIL; GLYCEROL; LATANOPROST; LEVOBUNOLOL; MANNITOL; MITOMYCIN C; OSMOTIC AGENT; PILOCARPINE; PROSTAGLANDIN; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER; UREA;

ARGON LASER; BRADYCARDIA; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYCLOPHOTOCOAGULATION; DIODE LASER; DROWSINESS; DRUG COST; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; EXERCISE TOLERANCE; EYE DISEASE; FATIGUE; FILTERING OPERATION; GLAUCOMA; GLAUCOMA DRAINAGE IMPLANT; HEART DISEASE; HUMAN; HYPEREMIA; IMPOTENCE; INCISION; INTRACTABLE PAIN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LASER COAGULATION; METALLIC TASTE; NEODYMIUM LASER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SYSTEMIC DISEASE; TASTE DISORDER; TECHNOLOGY; TRABECULECTOMY; TRABECULOPLASTY; VISION;

ANTIHYPERTENSIVE AGENTS; DECISION SUPPORT TECHNIQUES; FILTERING SURGERY; GLAUCOMA; GLAUCOMA DRAINAGE IMPLANTS; HUMANS; INTRAOCULAR PRESSURE; PRACTICE GUIDELINES;

EID: 1842556467     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-200404000-00011     Document Type: Review

References (65)

1. Collaborative Normal-tension Glaucoma Study Group: Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998, 126:487-497.
2. Collaborative Normal-tension Glaucoma Study Group: The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998, 126:498-505.
3. The AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS) 7: The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000, 130:429-440.
4. Lichter PR, Musch DC, Gillespie BW, et al., for the CIGITS Study Group.: Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medication or surgery. Ophthalmology 2001, 108:1943-1953.
5. Kass MA, Heuer DK, Higginbotham EJ, et al., and the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002, 120:701-713. Large, randomized, prospective, multicenter study that examined the effects of treatment versus nontreatment in ocular hypertensives. The goal in the medication group was to reduce the IOP by 20% or more and to reach an IOP of 24 mm Hg or less. At 5 years, the cumulative probability of developing primary open-angle glaucoma was 4.4% in the medication group and 9.5% in the observation group.
6. Heijl A, Leske MC, Bengtsson B, et al.: Reduction of intraocular pressure and glaucoma progression. Results form the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002, 120:1268-1279. Large, randomized prospective study performed in Sweden to evaluate glaucomatous progression in patients with early manifest glaucoma Two hundred fifty-five patients with open-angle glaucoma were randomized to ALT plus topical betaxolol or no treatment and were followed up every 3 months. Results showed that treated patients had half the risk of progression of their nontreated counterparts. Disk hemorrhage, higher IOP, pseudoexfoliation, worse mean deviation, and older age were all risk factors for progression.
7. American Academy of Ophthalmology Preferred Practice Patterns Committee Glaucoma Panel: Preferred practice patterns. Primary open angle glaucoma. San Francisco, CA: American Academy of Ophthalmology; 2001:1-38.
8. The Glaucoma Laser Trial Research Group: The Glaucoma Laser Trial (GLT) 2. Results of argon laser trabeculoplasty versus topical medications. Ophthalmology 1990, 97:1403-1413.
9. The AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcome within race. Seven year results. Ophthalmology 1998, 105:1146-1164.
10. Physicians Desk Reference for Ophthalmic Medicines. Montvale, NJ: Medical Economics, Inc.; 2003.
11. Netland PA, Kolker AE: Osmotic drugs. In Glaucoma Medical Therapy: Principle and Management. Edited by Netland PA, Allen RC. Foundation of the American Academy of Ophthalmology; 1999:133-147.
12. Tsai JC, Forbes M: Medical Management of Glaucoma. Caddo, Oklahoma: Professional Communications Inc.; 2003.
13. Camras CB, Toris CB, Tamesis RR: Efficacy and adverse effects of medications used in the treatment of glaucoma. Drugs Aging 1999, 15:377-388.
14. Eisenberg DL, Toris CB, Camras CB: Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol 2002, 47(suppl 1):S105-S115. Review article evaluating two studies that compare bimatoprost and travoprost with timolol and latanoprost. Each study supports the conclusion that these agents were more effective than timolol and as effective as latanoprost in terms of their ability to reduce IOP.
15. Susanna R, Giampini J, Borges AS, et al.: A double-masked randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology 2001, 108:259-263.
16. Jampel HD, Bacharach J, Sheu WP, et al.: Latanoprost/Unoprostone Study Group. Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure. Am J Ophthalmol 2002, 134:863-871. Randomized clinical trial comparing efficacy of latanoprost versus unoprostone in lowering IOP. During an 8-week study period, latanoprost once daily lowered IOP more than unoprostone twice daily in patients with elevated IOP.
17. Dubiner H, Cooke D, Dirks M, et al.: Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 2001, 45(suppl 4):S353-S360.
18. Gandolfi S, Simmons ST, Sturm R, et al.: Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001, 18:110-121.
19. Noecker RS, Dirks MS, Choplin NT, et al.: Bimatoprost/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003, 135:55-63. Six-month randomized, multicenter study comparing the IOP-lowering effect of bimatoprost with latanoprost. The study concluded that bimatoprost was more effective than latanoprost in lowering IOP. A greater incidence of conjunctival hyperemia and eyelash growth were found in the bimatoprost group.
20. Netland PA, Landry T, Sullivan EK, et al.: Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001, 132:472-484.
21. Palmberg PF: Personal communication.
22. Noecker RJ, Earl ML, Mundorf T, et al.: Bimatoprost 0.03% versus travoprost 0.004% in black Americans with glaucoma or ocular hypertension. Adv Ther 2003, 20:121-128. Randomized, multicenter, parallel design trial comparing the IOP-lowering efficacy of bimatoprost versus travoprost in black Americans. Results showed that after 3 months, mean IOP reduction from baseline was 8,4 mm Hg in the bimatoprost group and 7.9 mm Hg in the travoprost group. This relatively small study-16 patients were enrolled in the bimatoprost group and 15 in the travoprost group-is a precursor to a larger clinical trial.
23. Parrish RK, Palmberg P, Sheu WP and the XLT Study Group: A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003, 135:688-703. This well-designed interventional study compared the IOP-lowering effect and safety of latanoprost, bimatoprost, and travoprost in patients with open-angle glaucoma or ocular hypertension. Results showed comparable efficacy in pressure lowering among the three agents, with latanoprost having the least adverse ocular side effects.
24. Strahlman E, Tipping R, Vogel R: A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol 1995, 113:1009-1016.
25. Schuman JS, Horwitz B, Choplin NT, et al,: A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997, 115:847-852.
26. LeBlanc RP: Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology 1998, 105:1960-1967.
27. Kass MA, Meltzer DW, Gordon M, et al.: Compliance with topical pilocarpine treatment. Am J Ophthalmol 1986, 101:515-523.
28. Kass MA, Gordon M, Morley RE Jr, et al.: Compliance with topical timolol treatment. Am J Ophthalmol 1987, 103:188-193.
29. Greenberg RN: Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984, 6:592-599.
30. Fiscella RG, Green A, Patuszynski DH, et al.: Medical therapy cost considerations for glaucoma. Am J Ophthalmol 2003, 136:18-25. This study attempted to calculate the daily patient cost of medical glaucoma therapy and review cost trends. Findings were that all generic timolol, Betimol, OptiPranolol, Timoptic, and Timoptic XE ranged from 38 cents to 50 cents per day. Cosopt (US$1.05 per day) was less costly than separate bottles of a topical β-blocker and a topical carbonic anhydrase inhibitor. The prostaglandin analogs ranged from 90 cents per day (Rescula) to $1.25 per day (Xalatan).
31. Gonzalez: Serafin, RPh, Pharmacy Director, Anne Bates Leach Eye Hospital. Personal communication.
32. Asrani S, Zeimer Wilensky J, Gieser D, et al.: Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000, 9:134-142.
33. Orzalesi N, Rossetti L, Invernizzi T, et al.: Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 2000, 41:2566-2573.
34. Brubaker RF: Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am J Ophthalmol 1996, 121:473-483.
35. Leibowitz HM, Krueger DE, Maunder LR, et al.: The Framingham Eye Study monograph: An ophthalmological epidemiological survey of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980, 24(suppl):335-610.
36. Sommer A, Tielsch JM, Katz J, et al.: Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans: The Baltimore Eye Survey. Arch Opthalmol 1991, 109:1090-1095.
37. Uram M: Ophthalmic laser microendoscope ciliary process ablation in the management of neovascular glaucoma. Ophthalmology 1992, 99:1823-1828.
38. Bartamian M, Higginbotham EJ: What is on the horizon for cycloablation? Curr Opin Ophthalmol 2001, 12:119-123.
39. Egbert PR, Fiadoyor S, Budenz DL, et al.: Diode laser transscleral cyclophotocoagulation as a primary surgical treatment for primary open-angle glaucoma. Arch Ophthalmol 2001, 119:345-350.
40. Wise JB, Witter SL: Argon laser therapy for open-angle glaucoma. A pilot study. Arch Ophthalmol 1979, 97:319-322.
41. Wise JB: Long-term control of adult open angle glaucoma by argon laser treatment. Ophthalmology 1981, 88:197-202.
42. Greenidge KC, Spaeth GL, Fiol-Silva Z: Effect of argon laser trabeculoplasty on the glaucomatous diurnal curve. Ophthalmology 1983, 90:800-804.
43. Shingleton BJ, Richter CU, Dharma SK, et al.: Long-term efficacy of argon laser trabeculoplasty. A 10-year follow-up study. Ophthalmology 1993, 100:1324-1329.
44. Rodrigues MM, Spaeth GL, Donohoo P: Electron microscopy of argon laser therapy in phakic open-angle glaucoma. Ophthalmology 1982, 89:198-210.
45. Melamed S, Pei J, Epstein DL: Delayed response to argon laser trabeculoplasty in monkeys. Morphological and morphometric analysis. Arch Ophthalmol 1986, 104:1078-1083.
46. Schwartz AL: Argon laser trabeculoplasty in glaucoma: What's happening (survey results of American Glaucoma Society members). J Glaucoma 1993, 2:329-335.
47. Latina MA, Sibayan SA, Shin DH, et al.: Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty): a multicenter, pilot, clinical study. Ophthalmology 1998, 105:2082-2088.
48. Latina MA, Tumbocon JA: Selective laser trabeculoplasty: a new treatment option for open angle glaucoma. Curr Opin Ophthalmol 2002, 13:94-96.
49. Kramer TR, Noecker RJ: Comparison of the morphologic changes after selective laser trabeculoplasty and argon laser trabeculoplasty in human eye bank eyes. Ophthalmology 2001, 108:773-779.
50. Damji KF, Shah RC, Rock WJ: Selective laser trabeculoplasty v argon laser trabeculoplasty: A prospective randomized clinical trial. Br J Ophthalmol 1999, 83:718.
51. Melamed S, Ben Simon GJ, Levkovitch-Verbin H: Selective laser trabeculoplasty as primary treatment for open-angle glaucoma. A prospective, nonrandomized pilot study. Arch Ophthalmol 2003, 121:957-960. This study explored the safety and efficacy of SLT as primary treatment for patients with open-angle glaucoma. Forty-five eyes of 31 patients with open-angle glaucoma or ocular hypertension underwent SLT as primary treatment. Eighty-nine percent had a decrease of 5 mm Hg or more. The study concluded that SLT is a safe and effective treatment for newly diagnosed ocular hypertension and open-angle glaucoma.
52. http://www.som.tulane.edu/tccep/slt/slt.htm
53. Fluorouracil Filtering Surgery Study one-year follow-up: The Fluorouracil Filtering Study Group. Am J Ophthalmol 1989, 108:625-635.
54. Three year follow-up of the Fluorouracil Filtering Surgery Study: The Fluorouracil Filtering Study Group. Am J Ophthalmol 1993, 115:82-92.
55. Chen CW: Enhanced intraocular pressure controlling effectiveness of trabeculectomy by local application of mitomycin-C. Trans Asia-Pacific Acad Ophthalmol 1983, 9:172-177.
56. Palmer SS: Mitomycin as adjunct chemotherapy with trabeculectomy. Ophthalmology 1991, 98:317-321.
57. Singh K, Mehta K, Shaikh NM, et al.: Trabeculectomy with intraoperative mitomycin C versus 5-fluorouracil. Prospective randomized clinical trial. Ophthalmology 2000, 107:2305-2309.
58. Lachkar Y, Hamard P: Nonpenetrating filtering surgery. Curr Opin Ophthalmol 2002, 13:110-115. This article provides a thorough review of the various modalities of nonpenetrating filtering surgery. The article examines techniques, efficacy, and results from clinical trials.
59. Carassa RG, Bettin P, Fiori M, Brancato R: Viscocanalostomy versus trabeculectomy in white adults affected by open-angle glaucoma: a 2-year randomized, controlled trial. Ophthalmology 2003, 110:882-887. Single-masked, prospective, randomized 24 month trial comparing the effectiveness and safety of viscocanalostomy and trabeculectomy in adults with uncontrolled open-angle glaucoma. The group randomized to viscocanalostomy achieved IOP between 6 mm Hg and 21 mm Hg 76% of the time versus 80% of the time for trabeculectomy with no intraoperative antimetabolites. A lower pressure, albeit with a greater complication rate and more labor-intensive postoperative course, was achieved more often with trabeculectomy.
60. Wilson MR, Mendis U, Smith SD, et al.: Ahmed glaucoma valve implant vs trabeculectomy in the surgical treatment of glaucoma: a randomized clinical trial. Am J Ophthalmol 2000, 130:267-273.
61. Janz NK, Wren PA, Lichter PR, et al.: CIGTS Study Group. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology 2001, 108:1954-1965.
62. Mermoud A, Salmon JF, Alexander P, et al.: Molteno tube implantation for neovascular glaucoma. Long-term results and factors influencing the outcome. Ophthalmology 1993, 100:897-902.
63. Sidoti PA, Dunphy TR, Baerveldt G, et al.: Experience with the Baerveldt glaucoma implant in treating neovascular glaucoma. Ophthalmology 1995, 102:1107-1118.
64. Ceballos EM, Parrish RK 2nd, Schiffman JC: Outcome of Baerveldt glaucoma drainage implants for the treatment of uveitic glaucoma. Ophthalmology 2002, 109:2256-2260. Retrospective, noncomparative case series that looked at 24 eyes of 24 patients who received Baerveldt glaucoma drainage implants for the treatment of uveitic glaucoma. Success (IOP 5 to 21 mm Hg) was achieved in 91. 7% of the patients at 24 months. The study concluded that these drainage implants provide reasonable safety and effectiveness for the control of IOP in eyes with uveitis and refractory glaucoma.
65. Chen PP, Yamamoto T, Sawada A, et al.: Use of antifibrosis agents and glaucoma drainage devices in the American and Japanese Glaucoma Societies. J Glaucoma 1997, 6:192-196.